Business
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.
About this update from Grail, Inc.
[{"type":"text","content":"Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"Completed Galleri PMA Submission to FDA","length":39,"tagName":"p","attribs":{}},{"type":"text","content":"Shared Topline Results from the NHS-Galleri Trial","length":49,"tagName":"p","attribs":{}},{"type":"text","content":"Completed Analysis of the Full 35k Participant PATHFINDER 2 Study","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"Strong Financial Position with Cash into 2030","length":45,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.","length":284,"tagName":"p"},{"type":"image","alt":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","displaySize":"","headline":null,"caption":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":76,"url":"https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LnMp0pobetiqZw3skecvAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","width":400,"height":76}},"href":"https://mma.prnewswire.com/media/2460831/Grail_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fourth quarter total revenue grew 14% year-over-year to $43.6 million, and U.S. Galleri revenue grew 31% year over year to $41.3 million. Net loss was $99.2 million, which includes amortization of Illumina acquisition-related intangible items of $34.6 million. Gross loss was $11.1 million. Non-GAAP adjusted gross profit was $23.1 million, and non-GAAP adjusted EBITDA was $(71.8) million.1","length":391,"tagName":"p"},{"type":"text","content":"For the full year total revenue grew 17% year over year to $147.2 million, and U.S. Galleri revenue grew 26% ...